EGFR T790M mutation
MALDI-TOF mass spectrometry
droplet digital PCR (ddPCR)
real time quantitative PCR (AS-PCR)
ultra-deep next generation sequencing (NGS)
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
entrez:
19
11
2019
pubmed:
19
11
2019
medline:
19
11
2019
Statut:
ppublish
Résumé
Routine testing of baseline We compared the diagnostic performance, sensitivity and specificity of three methods, namely MALDI-TOF mass spectrometry (MS), Allele-Specific Real Time PCR (AS-PCR), droplet digital PCR (ddPCR). Ultra-deep next generation sequencing (NGS) validation of T790M-mutant NSCLCs was performed using SiRe Baseline T790M occurred in 17% of the tumors. Intermediately sensitive techniques such as MALDI-TOF MS (detection limit of T790M ≥5%) allow to detect T790M in 2% of cases exhibiting mutant-allele fractions ranging from 11.5% to 17%. Median overall survival (OS) in these patients was poor (7.3 months) and progression free survival (PFS) was of 3.3 months in patients treated with a 1st generation EGFR TKI. The remaining T790M-positive cases showed very low mutant-allele fractions ranging from 0.07% to 0.38% and required highly sensitive methods such as ddPCR and NGS to be identified. All these cases showed a concurrent sensitizing Routine test of baseline
Sections du résumé
BACKGROUND
BACKGROUND
Routine testing of baseline
METHODS
METHODS
We compared the diagnostic performance, sensitivity and specificity of three methods, namely MALDI-TOF mass spectrometry (MS), Allele-Specific Real Time PCR (AS-PCR), droplet digital PCR (ddPCR). Ultra-deep next generation sequencing (NGS) validation of T790M-mutant NSCLCs was performed using SiRe
RESULTS
RESULTS
Baseline T790M occurred in 17% of the tumors. Intermediately sensitive techniques such as MALDI-TOF MS (detection limit of T790M ≥5%) allow to detect T790M in 2% of cases exhibiting mutant-allele fractions ranging from 11.5% to 17%. Median overall survival (OS) in these patients was poor (7.3 months) and progression free survival (PFS) was of 3.3 months in patients treated with a 1st generation EGFR TKI. The remaining T790M-positive cases showed very low mutant-allele fractions ranging from 0.07% to 0.38% and required highly sensitive methods such as ddPCR and NGS to be identified. All these cases showed a concurrent sensitizing
CONCLUSIONS
CONCLUSIONS
Routine test of baseline
Identifiants
pubmed: 31737495
doi: 10.21037/tlcr.2019.09.18
pii: tlcr-08-05-584
pmc: PMC6835109
doi:
Types de publication
Journal Article
Langues
eng
Pagination
584-592Commentaires et corrections
Type : CommentIn
Informations de copyright
2019 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Oncotarget. 2017 Oct 12;8(58):98384-98393
pubmed: 29228697
Clin Cancer Res. 2011 Mar 1;17(5):1169-80
pubmed: 21248300
Clin Cancer Res. 2011 Mar 1;17(5):1160-8
pubmed: 21233402
J Clin Pathol. 2019 Jan;72(1):38-45
pubmed: 30279174
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Annu Rev Med. 2008;59:429-42
pubmed: 17716025
Nat Genet. 2005 Dec;37(12):1315-6
pubmed: 16258541
Ann Oncol. 2014 Feb;25(2):423-8
pubmed: 24478319
Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S127-S130
pubmed: 29782562
Lung Cancer. 2016 Apr;94:46-53
pubmed: 26973206
Lung Cancer. 2017 Jun;108:83-89
pubmed: 28625654
Clin Cancer Res. 2014 Dec 1;20(23):5898-907
pubmed: 25303979
J Clin Oncol. 2008 May 20;26(15):2442-9
pubmed: 18458038
J Clin Oncol. 2012 Feb 1;30(4):433-40
pubmed: 22215752
Lancet Respir Med. 2017 May;5(5):435-444
pubmed: 28408243
Clin Cancer Res. 2014 Apr 1;20(7):2001-10
pubmed: 24493829
J Clin Oncol. 2006 Apr 10;24(11):1700-4
pubmed: 16505411
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
Br J Cancer. 2017 Mar 14;116(6):802-810
pubmed: 28170370
Lung Cancer. 2017 Aug;110:7-13
pubmed: 28676222
N Engl J Med. 2008 Jul 24;359(4):366-77
pubmed: 18596266
Clin Cancer Res. 2011 Jun 1;17(11):3812-21
pubmed: 21531810
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
J Thorac Oncol. 2012 Nov;7(11):1640-4
pubmed: 22899358
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
J Thorac Dis. 2018 Apr;10(4):2311-2320
pubmed: 29850136